公开(公告)号：EP1692278B1

公开(公告)日：2013-07-03

申请号：EP04789595.8

申请日：2004-10-20

申请人： Melbourne Health ,  Austin Health ,  Southern Health ,  Alfred Health ,  St. Vincent's Hospital (Melbourne) Ltd. trading as St. Vincent's Hospital Melbourne

发明人： BARTHOLOMEUSZ, Angeline, Ingrid ,  LOCARNINI, Stephen, Alister ,  AYRES, Anna ,  YUEN, Lilly, Ka Wai ,  SASADEUSZ, Joseph, John ,  Angus, Peter William ,  Sievert, William ,  Lewin, Sharon Ruth ,  Desmond, Paul Vincent ,  Bell. Sally Jane

IPC分类号： C12N7/00 ,  C12Q1/70 ,  C07K14/005

CPC分类号： C07K14/005 ,  A61K39/00 ,  C12N7/00 ,  C12N2730/10122 ,  C12Q1/706

公开(公告)号：EP2404933A3

公开(公告)日：2012-04-25

申请号：EP10186050.0

申请日：2004-10-20

申请人： Melbourne Health ,  Austin Health ,  Southern Health ,  St. Vincent's Hospital (Melbourne) Ltd. trading as St. Vincent's Hospital Melbourne ,  Alfred Health

发明人： Bartholomeusz, Angeline Ingrid ,  Locarnini, Stephen Alister ,  Ayres, Anna ,  Yuen, Lilly Ka Wei ,  Sasadeusz, Joseph John ,  Angus, Peter William ,  Sievert, William ,  Lewin, Sharon Ruth ,  Desmond, Paul Vincent ,  Bell, Sally Jane

IPC分类号： C07K14/02 ,  C12N7/00

CPC分类号： C07K14/005 ,  A61K39/00 ,  C12N7/00 ,  C12N2730/10122 ,  C12Q1/706

摘要： The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.

公开(公告)号：EP2404933A2

公开(公告)日：2012-01-11

申请号：EP10186050.0

申请日：2004-10-20

申请人： Melbourne Health ,  Austin Health ,  Southern Health ,  St. Vincent's Hospital (Melbourne) Ltd. trading as St. Vincent's Hospital Melbourne ,  Alfred Health

发明人： Bartholomeusz, Angeline Ingrid ,  Locarnini, Stephen Alister ,  Ayres, Anna ,  Yuen, Lilly Ka Wei ,  Sasadeusz, Joseph John ,  Angus, Peter William ,  Sievert, William ,  Lewin, Sharon Ruth ,  Desmond, Paul Vincent ,  Bell, Sally Jane

IPC分类号： C07K14/02 ,  C12N7/00

CPC分类号： C07K14/005 ,  A61K39/00 ,  C12N7/00 ,  C12N2730/10122 ,  C12Q1/706

摘要： The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.

摘要翻译： 本发明一般涉及对特定试剂显示降低的敏感性和/或与免疫试剂的交互性降低的病毒变体。 更具体地说，本发明涉及对核苷或核苷酸类似物显示完全或部分抗性和/或与抗病毒表面成分的抗体交互性降低的乙型肝炎病毒（HBV）变体，包括降低对这些抗体的敏感性。 本发明进一步考虑用于检测这种病毒变体的测定法，该测定法可用于监测抗病毒治疗方案和开发针对病毒药物特别是HBV变体的新型或改性疫苗。 本发明还考虑使用病毒变体筛选和/或开发或设计能够抑制病毒感染，复制和/或释放的药剂。